Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3517 - Mirvetuximab soravtansine, a folate receptor alpha (FR_)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a Phase Ib study

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Clinical Research

Tumour Site

Ovarian Cancer

Presenters

Ursula Matulonis

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

U.A. Matulonis1, K.N. Moore2, L.P. Martin3, I.B. Vergote4, C. Castro5, L. Gilbert6, K. Malek7, M.J. Birrer8, D.M. O'Malley9

Author affiliations

  • 1 Medical Oncology, Dana Farber Cancer Institute, 02115 - Boston/US
  • 2 Gynecologic Oncology, Stephenson Cancer Center/University of Oklahoma, 73104 - Oklahoma City/US
  • 3 Department Of Hematology/oncology, Fox Chase Cancer Center, 19111-2497 - Philadelphia/US
  • 4 Gynaecology, University Hospitals Leuven, 3000 - Leuven/BE
  • 5 Medical Oncology, Massachusetts General Hospital, 02115 - Boston/US
  • 6 Obstetrics And Gynecology, McGill University Health Center, Montreal/CA
  • 7 Clinical Development, Immuno Gen Inc., MA 02451 - Waltham/US
  • 8 Division Of Hematology-oncology, University of Alabama at Birmingham, 35294-3300 - Birmingham/US
  • 9 Clinical research Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus/US
More

Resources

Abstract 3517

Background

Mirvetuximab soravtansine is an ADC comprised of a FRα-binding antibody linked to the tubulin-disrupting maytansinoid DM4. This agent activates monocytes and upregulates immunogenic cell death markers on ovarian tumor cells, providing a rationale for combining with immune checkpoint blockade. Mirvetuximab soravtansine is being evaluated in combination with pembrolizumab in patients with PROC.

Methods

Eligibility criteria include FRα positivity by IHC (≥ 25% of cells with ≥ 2+ staining intensity), 2-4 prior systemic treatments, and no prior immunotherapy. Mirvetuximab soravtansine (6 mg/kg; adjusted ideal body weight) and pembrolizumab (200 mg) were administered intravenously on day 1 of a 21-day cycle. Responses were assessed with RECIST 1.1 and adverse events (AEs) by CTCAE v4.03.

Results

During dose-escalation (n = 14 patients), the mirvetuximab soravtansine-pembrolizumab combination demonstrated favorable tolerability, with primarily ≤ grade 2 AEs observed. Overall, the AE profile was manageable and consistent with the known profiles of each agent. In addition, promising evidence of durable antitumor activity was observed, including a confirmed objective response rate of 43%, median duration of response of 6.9 months, and median progression-free survival of 5.2 months. These findings supported enrollment of an expansion cohort to further evaluate this combination in the setting of PROC. At time of analysis, 37/46 patients were enrolled, who received a median of 3 prior regimens. Median age was 62y (range 40-77), and 92% had tumors with high grade serous histology. Initial safety, antitumor activity, and exploratory biomarker data will be presented, including for the subset of patients with medium/high FRα expression, which showed the highest degree of clinical activity during escalation.

Conclusions

Preliminary data have demonstrated a manageable safety profile and encouraging signals of clinical activity for the mirvetuximab soravtansine-pembrolizumab combination in recurrent PROC. The results of this expansion cohort will guide further development of this novel combination.

Clinical trial identification

NCT02606305.

Legal entity responsible for the study

ImmunoGen, Inc.

Funding

ImmunoGen, Inc.

Editorial Acknowledgement

Disclosure

U.A. Matulonis, K.N. Moore, L.P. Martin, M.J. Birrer, D.M. O’Malley: Advisory board: ImmunoGen, Inc. I.B. Vergote: Advisory board: ImmunoGen, Inc. K. Malek: Employee: ImmunoGen, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.